Mostrar el registro sencillo del ítem

dc.contributor.author
Li, Xiaolin  
dc.contributor.author
Wang, Duowei  
dc.contributor.author
Chen, Zen  
dc.contributor.author
Lu, Ermei  
dc.contributor.author
Wang, Zhuo  
dc.contributor.author
Duan, Jingjing  
dc.contributor.author
Tian, Wei  
dc.contributor.author
Wang, Yun  
dc.contributor.author
You, Linjun  
dc.contributor.author
Zou, Yulian  
dc.contributor.author
Cheng, Yan  
dc.contributor.author
Zhu, Qingyi  
dc.contributor.author
Wan, Xiaojian  
dc.contributor.author
Xia, Tao  
dc.contributor.author
Birnbaumer, Lutz  
dc.contributor.author
Yang, Yong  
dc.date.available
2020-01-03T19:42:25Z  
dc.date.issued
2015-04-14  
dc.identifier.citation
Li, Xiaolin; Wang, Duowei; Chen, Zen; Lu, Ermei; Wang, Zhuo; et al.; Galphai1 and Galphai3 regulate macrophage polarization by forming a complex containing CD14 and Gab1; National Academy of Sciences; Proceedings of the National Academy of Sciences of The United States of America; 112; 15; 14-4-2015; 4731-4736  
dc.identifier.issn
0027-8424  
dc.identifier.uri
http://hdl.handle.net/11336/93463  
dc.description.abstract
Heterotrimeric G proteins have been implicated in Toll-like receptor 4 (TLR4) signaling in macrophages and endothelial cells. However, whether guanine nucleotide-binding protein G(i) subunit alpha-1 and alpha-3 (Gαi1/3) are required for LPS responses remains unclear, and if so, the underlying mechanisms need to be studied. In this study, we demonstrated that, in response to LPS, Gαi1/3 form complexes containing the pattern recognition receptor (PRR) CD14 and growth factor receptor binding 2 (Grb2)-associated binding protein (Gab1), which are required for activation of PI3K-Akt signaling. Gαi1/3 deficiency decreased LPS-induced TLR4 endocytosis, which was associated with decreased phosphorylation of IFN regulatory factor 3 (IRF3). Gαi1/3 knockdown in bone marrow-derived macrophage cells (Gαi1/3 KD BMDMs) exhibited an M2-like phenotype with significantly suppressed production of TNF-α, IL-6, IL-12, and NO in response to LPS. The altered polarization coincidedwith decreased Akt activation. Further, Gαi1/3 deficiency caused LPS tolerance in mice. In vitro studies revealed that, in LPS-tolerant macrophages, Gαi1/3 were down-regulated partially by the proteasome pathway. Collectively, the present findings demonstrated that Gαi1/3 can interact with CD14/Gab1, which modulates macrophage polarization in vitro and in vivo.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
National Academy of Sciences  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
ENDOSOME  
dc.subject
GΑI1  
dc.subject
GΑI3  
dc.subject
MACROPHAGE POLARIZATION  
dc.subject
TOLL-LIKE RECEPTOR 4  
dc.subject.classification
Bioquímica y Biología Molecular  
dc.subject.classification
Ciencias Biológicas  
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS  
dc.title
Galphai1 and Galphai3 regulate macrophage polarization by forming a complex containing CD14 and Gab1  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2019-10-28T18:25:11Z  
dc.journal.volume
112  
dc.journal.number
15  
dc.journal.pagination
4731-4736  
dc.journal.pais
Estados Unidos  
dc.description.fil
Fil: Li, Xiaolin. China Pharmaceutical University. Center for New Drug Safety Evaluation and Research; China  
dc.description.fil
Fil: Wang, Duowei. China Pharmaceutical University. Center for New Drug Safety Evaluation and Research; China  
dc.description.fil
Fil: Chen, Zen. China Pharmaceutical University. Center for New Drug Safety Evaluation and Research; China  
dc.description.fil
Fil: Lu, Ermei. China Pharmaceutical University. Center for New Drug Safety Evaluation and Research; China  
dc.description.fil
Fil: Wang, Zhuo. China Pharmaceutical University. Center for New Drug Safety Evaluation and Research; China  
dc.description.fil
Fil: Duan, Jingjing. China Pharmaceutical University. Center for New Drug Safety Evaluation and Research; China  
dc.description.fil
Fil: Tian, Wei. China Pharmaceutical University. Center for New Drug Safety Evaluation and Research; China  
dc.description.fil
Fil: Wang, Yun. China Pharmaceutical University. Center for New Drug Safety Evaluation and Research; China  
dc.description.fil
Fil: You, Linjun. China Pharmaceutical University. Center for New Drug Safety Evaluation and Research; China  
dc.description.fil
Fil: Zou, Yulian. China Pharmaceutical University. Center for New Drug Safety Evaluation and Research; China  
dc.description.fil
Fil: Cheng, Yan. China Pharmaceutical University. Center for New Drug Safety Evaluation and Research; China  
dc.description.fil
Fil: Zhu, Qingyi. Jiangsu Province Hospital of Traditional Chinese Medicine. Departament of Urology; China  
dc.description.fil
Fil: Wan, Xiaojian. Second Military Medical University. Department of Anesthesiology and Intensive Care Medicine, Changhai Hospita; China  
dc.description.fil
Fil: Xia, Tao. China Pharmaceutical University. Center for New Drug Safety Evaluation and Research; China  
dc.description.fil
Fil: Birnbaumer, Lutz. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. National Institute of Environmental Health Sciences. Laboratory of Neurobiology, ; Estados Unidos  
dc.description.fil
Fil: Yang, Yong. China Pharmaceutical University. Center for New Drug Safety Evaluation and Research; China  
dc.journal.title
Proceedings of the National Academy of Sciences of The United States of America  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.pnas.org/content/112/15/4731  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403188/  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1073/pnas.1503779112